PUBLISHER: The Business Research Company | PRODUCT CODE: 1729121
PUBLISHER: The Business Research Company | PRODUCT CODE: 1729121
Neurotrophic keratitis treatment refers to the therapies and medical interventions designed to manage and treat neurotrophic keratitis (NK), a rare degenerative disease of the cornea caused by impaired corneal nerve function. This condition leads to decreased or absent corneal sensation, resulting in impaired healing, persistent epithelial defects and corneal ulceration, which can progress to perforation in severe cases. comprises pharmaceutical drugs, surgical interventions and regenerative therapies aimed at restoring corneal integrity, preventing complications and improving patients' vision and quality of life.
The neurotrophic keratitis treatment market consists of sales of neurotrophic keratitis treatments and related services by entities (organizations, sole traders and partnerships) that develop and provide treatments to address the underlying nerve damage, promote corneal healing and prevent disease progression. The use of neurotrophic keratitis treatments depends on the severity of the disease, which is classified into three stages: early-stage epithelial irregularities (Stage I), persistent epithelial defects (Stage II) and corneal ulceration or perforation (Stage III).
The global neurotrophic keratitis treatment market was valued at $313.69 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 27.00%.
High Prevalence Of Diabetes
The high prevalence of diabetes drove the growth of the neurotrophic keratitis treatment market during the historic period. Chronic hyperglycemia in diabetic patients can lead to diabetic neuropathy, which affects the corneal nerves, impairing their ability to detect and respond to injuries. This increases the likelihood of developing neurotrophic keratitis, as the cornea loses its protective reflexes and healing capacity, making it more vulnerable to ulcers and infections. For example, according to the International Diabetes Federation (IDF), a Belgium-based umbrella organization of national diabetes associations, diabetes affected 537 million adults aged 20-79 worldwide in 2021, with over three-quarters residing in low- and middle-income countries. The disease caused approximately 6.7 million deaths, equating to one death every five seconds. Health expenditures related to diabetes reached USD 966 billion, marking a 316% increase over the past 15 years. Further, 541 million adults had impaired glucose tolerance (IGT), heightening their risk of developing type 2 diabetes. Additionally, according to the National Diabetes Statistics Report published by the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, 11.6% of US citizens or 38.4 million people of all ages, suffered from diabetes in 2021. With age, the percentage of people with diabetes rose and among those 65 years of age or older, it reached 29.2%. Therefore, the high prevalence of diabetes contributed to the growth of the neurotrophic keratitis treatment market.
Revolutionizing Keratoconus Treatment With Contoured Corneal Tissue Segments
Major companies operating in the neurotrophic keratitis treatment market are focusing on revolutionizing keratoconus treatment with contoured corneal tissue segments. By developing contoured corneal tissue segments, companies aim to improve the structural integrity of the cornea while also potentially promoting nerve regeneration and better healing. These segments can be precisely designed to match the patient's specific corneal anatomy, offering a personalized treatment approach that enhances both mechanical stability and sensory function. For instance, in June 2024, CorneaGen, a US-based developer of medical devices, launched the Corneal Tissue Addition for Keratoplasty (CTAK), a solution designed for corneal contouring in keratoconic eyes. CTAK provides patient-ready, gamma-irradiated, sterile, non-immunogenic corneal tissue segments, laser-cut and customized to the patient's specific cone severity and location. This advancement aims to improve surgical outcomes and make optimal use of corneal donations.
The global neurotrophic keratitis treatment market is highly concentrated, with large player dominating the market. The top 1 competitor in the market made up 100% of the total market in 2023.
Neurotrophic Keratitis Treatment Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global neurotrophic keratitis treatment market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for neurotrophic keratitis treatment? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The neurotrophic keratitis treatment market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider neurotrophic keratitis treatment market; and compares it with other markets.